Cellulitis Treatment
For outpatients with nonpurulent cellulitis (no drainage or abscess), treat with a beta-lactam antibiotic targeting beta-hemolytic streptococci—specifically penicillin, amoxicillin, cephalexin, or cefazolin—for 5-10 days, reserving MRSA coverage only for patients who fail initial therapy or present with systemic toxicity. 1
Treatment Algorithm Based on Clinical Presentation
Nonpurulent Cellulitis (No Drainage, No Abscess)
This represents the majority of typical cellulitis cases and is primarily caused by beta-hemolytic streptococci, not MRSA 1, 2.
First-line therapy:
- Oral outpatient: Cephalexin 500 mg four times daily OR penicillin/amoxicillin 3
- IV inpatient: Cefazolin 1 g every 8 hours OR nafcillin/oxacillin 1-2 g every 4 hours 3
- Duration: 5-10 days based on clinical response 1, 2
When to add MRSA coverage:
- Patient fails to respond to beta-lactam therapy after 48-72 hours 1, 2
- Signs of systemic toxicity present 1
- Known MRSA risk factors (athletes, prisoners, IV drug users, prior MRSA) 4
Purulent Cellulitis (Drainage/Exudate Without Drainable Abscess)
Empirical MRSA coverage is mandatory pending culture results 1, 2.
Oral options for MRSA coverage:
- Clindamycin 300-450 mg three times daily (covers both MRSA and streptococci) 1
- TMP-SMX 1-2 double-strength tablets twice daily PLUS amoxicillin (TMP-SMX alone misses streptococci) 1
- Doxycycline 100 mg twice daily PLUS amoxicillin 1
- Linezolid 600 mg twice daily (covers both, but expensive) 1
Duration: 5-10 days based on clinical response 1
Complicated/Hospitalized Cellulitis
For patients requiring hospitalization with deeper infections, surgical wounds, major abscesses, or infected ulcers 1:
IV options:
- Vancomycin 30 mg/kg/day in 2 divided doses (drug of choice) 3
- Linezolid 600 mg IV/PO twice daily 1
- Daptomycin 4 mg/kg IV once daily 1
- Clindamycin 600 mg IV three times daily (if local resistance <10%) 1
Duration: 7-14 days based on clinical response 1
Critical Dosing Considerations
Weight-based dosing matters significantly for treatment success. Inadequate dosing is independently associated with clinical failure (OR 2.01) 5. Nearly half of obese patients receive suboptimal dosing 6.
Adequate dosing thresholds:
- Clindamycin: ≥10 mg/kg/day (not just 300 mg three times daily for larger patients) 5
- TMP-SMX: ≥5 mg TMP/kg/day 5
Pediatric Modifications
- Hospitalized children: Vancomycin 40 mg/kg/day in 4 divided doses OR clindamycin 10-13 mg/kg/dose every 6-8 hours (40 mg/kg/day total) if local resistance <10% 1, 2
- Linezolid: 10 mg/kg/dose every 8 hours for children <12 years; 600 mg twice daily for ≥12 years 1
- Avoid tetracyclines in children <8 years 1, 2
- Minor infections: Mupirocin 2% topical ointment three times daily 1
Common Pitfalls to Avoid
Do not routinely cover MRSA for nonpurulent cellulitis. Despite rising community-acquired MRSA rates, beta-hemolytic streptococci remain the primary pathogen in typical cellulitis without purulence 7, 4. Empirical MRSA coverage for nonpurulent cases leads to unnecessary broad-spectrum antibiotic use 8.
Do not use rifampin as monotherapy or adjunctive therapy for cellulitis 1.
Bilateral cellulitis is rare—consider alternative diagnoses like venous stasis dermatitis, contact dermatitis, or lymphedema 9, 7.
TMP-SMX alone is insufficient for purulent cellulitis if streptococcal coverage is needed; combine with a beta-lactam like amoxicillin 1.
Five days of therapy is sufficient if clinical improvement occurs; extending to 10-14 days should be reserved for slow responders 1, 2. Studies show no benefit of 10-14 days over 5-7 days when response is adequate 6.
Special Populations
Elderly patients on TMP-SMX: Increased risk of hyperkalemia, especially with concurrent ACE inhibitors/ARBs or chronic kidney disease 1.
Pregnant women: Avoid TMP-SMX in third trimester (Category C/D) 1.
Infants <2 months: Do not use TMP-SMX 1.